Workflow
中国医疗集团(08225) - 2023 Q3 - 季度财报
C HEALTH GPC HEALTH GP(HK:08225)2023-11-14 06:46

Financial Performance - For the nine months ended September 30, 2023, the group recorded revenue of approximately RMB 17,894,000, an increase of about 37% compared to RMB 13,090,000 for the same period in 2022[9] - The group achieved a profit before tax of approximately RMB 6,981,000, representing a significant increase of approximately 2,922% from RMB 231,000 in the same period of 2022[9] - Basic earnings per share for the nine months ended September 30, 2023, were approximately RMB 0.6 cents, up about 2,900% from RMB 0.02 cents in the same period of 2022[9] - Total comprehensive income for the nine months ended September 30, 2023, was RMB 5,934,000, a significant increase from RMB 192,000 in the same period of 2022[10] - The net profit for the period was approximately RMB 5,934,000, significantly up from RMB 192,000 in the same period of 2022[37] Dividends - The board of directors recommended not to declare any dividends for the nine months ended September 30, 2023[9] - The company did not recommend any dividend payment for the period ended September 30, 2023, consistent with the previous year[28] Operating Expenses - Administrative expenses decreased by 16% to RMB 4,254,000 for the nine months ended September 30, 2023, down from RMB 5,069,000 in the same period of 2022[21] Business Focus - The group continues to focus on providing integrated pharmaceutical services in China, including clinical research and medical marketing[14] - The company is committed to developing a comprehensive medical service group under an internet architecture[14] - The company is focusing on two new business models: RWS-Therapy and D-CRCO, aimed at redefining treatment and commercialization through real-world clinical research[30] Taxation - The effective corporate income tax rate for the period was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9%[24] Shareholder Information - As of September 30, 2023, the CEO and directors held a total of 132,851,941 shares, representing 13.35% of the company[47] - Major shareholders include Winsland Agents Limited with 349,368,873 shares (35.10%) and Venturepharm Holdings Inc. with 149,432,580 shares (15.01%) as of September 30, 2023[52] - The group closely monitors shareholder interests, with no additional disclosures of interests or holdings beyond those reported as of September 30, 2023[49] Stock Options - The stock option plan, approved on June 30, 2015, has a validity of 10 years, aimed at incentivizing qualified participants for their contributions to the group[53] - The stock option plan includes directors, employees, and contractors of the group as eligible participants, promoting long-term development[54] - The total number of stock options granted amounts to 25,380,000, with various exercise prices and dates[56] - The stock option plan aims to provide opportunities for participants to own shares, thereby aligning their interests with the group's long-term goals[54] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[64] - The company adhered to the corporate governance code as per GEM listing rules during the nine-month period ending September 30, 2023[61] - There were no competitive interests held by directors or management shareholders in any business that may compete with the company's operations[60] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[62] - The board of directors consists of two executive directors, one non-executive director, and three independent non-executive directors as of the report date[67] Financial Reporting - The financial statements have been prepared in accordance with the new revised Hong Kong Financial Reporting Standards[15] - The group has not yet applied the new Hong Kong Financial Reporting Standards that have been issued but not yet effective[16] - The company has a structured approach to internal controls and has provided adequate disclosures in its financial reporting[64] Assets and Liabilities - As of September 30, 2023, the company had no bank credit facilities or pledged assets[41][42] - The company has no significant investments or capital asset plans beyond those disclosed in the report[40] - The majority of the group's transactions during the review period were denominated in RMB, with ongoing monitoring of foreign currency risks and appropriate hedging as needed[45] - As of September 30, 2023, the company did not purchase, sell, or redeem any of its listed shares during the nine-month period[59] - The company maintains sufficient public float according to the information available as of the report date[65]